Novo Nordisk Adjusts Profit Forecast and Announces Global Layoffs
The renowned pharmaceutical leader, Novo Nordisk, has recently revised its 2025 profit growth predictions while unveiling plans to restructure its global workforce. The Danish company, celebrated for its advancements in obesity and diabetes treatments, is now grappling with intense competition in the weight-loss medication market.
Profit and Sales Performance
During its third-quarter financial review, Novo Nordisk reported a 30% decline in operating profit, amounting to DKK 23.7 billion—falling short of the DKK 24.6 billion anticipated by analysts. Despite a 5% rise in total sales to DKK 75.0 billion, figures still failed to meet forecasts of DKK 76.2 billion. The quarter also witnessed a notable underperformance of its star weight-loss drug, Wegovy, which garnered DKK 20.4 billion compared to the DKK 20.9 billion target.
CEO Mike Doustdar attributed these results to slower-than-expected growth in its GLP-1 treatments, including Wegovy and Ozempic. Ozempic reported DKK 95.3 billion in sales over nine months, reflecting a 10% increase in Danish kroner and a 13% rise in constant exchange rates.
Market Challenges and Workforce Restructuring
Novo Nordisk has seen its stock drop by a staggering 50% this year amidst mounting competition from U.S.-based pharmaceutical giant Eli Lilly, as well as the emergence of generic alternatives. Unsafe mass compounding practices of competing drugs have further added to the challenges.
To counter falling profit margins, the company is implementing a massive restructuring initiative, involving cutting 9,000 jobs globally, including 5,000 in Denmark. The restructuring costs, totaling DKK 8 billion, encompass DKK 5 billion in severance payouts and DKK 4 billion in asset impairments. This move is expected to produce savings of DKK 1 billion in the final quarter of the year.
Growth Areas Amid Challenges
While overall operating profit growth for the first nine months was 5% (excluding restructuring expenses), the contribution of obesity care has seen promising developments. Revenue from obesity treatments surged 37% in Danish kroner and 41% at constant exchange rates, driven by markets in Asia-Pacific (up 35%) and EUCAN (up 18%). Additionally, the U.S. market reported a 15% growth in obesity care at constant exchange rates.
One key milestone this quarter was the FDA’s approval of Wegovy for treating metabolic dysfunction-associated steatohepatitis (MASH). This breakthrough approval signals potential areas for future growth.
Looking Ahead
Novo Nordisk continues to innovate and expand its metabolic treatment portfolio. The company recently announced acquisitions of Akero Therapeutics and Omeros Corp.’s MASP-3 inhibitor zaltenibart.
Despite the challenges, Novo Nordisk remains a strong player in the healthcare industry, leveraging its pipeline of treatments. Patients seeking advanced weight-loss solutions such as Wegovy can explore options available through healthcare providers or pharmacies (discover Wegovy on GoodRx).
For investors looking for opportunities, it remains crucial to monitor Novo Nordisk’s next strategic steps. Meanwhile, the competition in the obesity care market promises innovation, making it an exciting field to watch.